RSS Feeds
Search

Articles

Pharmalicensing brings you advice, commentary and analysis from industry experts.

Articles

No results found for given criteria.
Please try to put more general criteria into your selection.

Related Reports

Market Research Reports provided by reports.iptechex.com
Exocrine Pancreatic Insufficiency Global Clinical Trials Review, Q1, 2011
Feb 2011 - 35 pages - $1,000
Marina Biotech: SWOT Analysis & Company Profile
Sep 2010 - 23 pages - $99
Eurand N.V. (EURX) - Financial and Strategic SWOT Analysis Review
Feb 2011 - 39 pages - $125
Eurand N.V. (EURX) - Financial and Strategic SWOT Analysis Review
May 2011 - 39 pages - $125
Metastatic Pancreatic Cancer - Pipeline Review, Q3 2011
Jul 2011 - 321 pages - $500
US FDA Approval of Afinitor Ends a Three Decade Long Wait for Pancreatic Neuroendocrine Tumor (PNET) Patients
May 2011 - 5 pages - $500
Altus Pharmaceuticals Inc.: Company Profile and SWOT Analysis
Sep 2011 - 29 pages - $99
Marina Biotech, Inc. - SWOT Analysis
Nov 2010 - 21 pages - $125
Pharmaceutical Company Outlook to 2015
Dec 2010 - 129 pages - $7,600
Hepatic Insufficiency Global Clinical Trials Review, Q2, 2011
May 2011 - 50 pages - $1,000
More Related Market Research Reports >>>

Your selection

Industry sector
Academic/Research del
Biotech del
Therapeutic target
Endocrinology del
Pancreatic exocrine insufficiency del
Year
2003 del

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us